ALNY

ALNYLAM PHARMACEUTICALS, INC.

Pharmaceutical Preparations · SIC 2834CIK 1178670Held by 8 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$3.71B

Net Income FY2025

$0.31B

EPS (Basic, as reported)

$2.39

Net Margin FY2025

8.4%

ROE FY2025

39.8%

Total Equity

$0.79B

Shares Out

134M

Business description

ALNYLAM PHARMACEUTICALS, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2008–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 47 → 3,714 +62.5% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue4790752204938441,0371,8282,2483,714

Cost of revenue—0(2)(25)(78)(115)(140)(268)(307)(677)

Research & development(382)(391)(505)(655)(655)(792)(883)(1,004)(1,126)(1,320)

Selling, general & administrative(89)(199)(382)(479)(588)(621)(771)(796)(976)(1,211)

General & administrative(89)(199)————————

Total operating expenses(472)(590)(890)(1,159)(1,321)(1,553)(1,822)(2,110)(2,425)(3,212)

Operating income(425)(500)(815)(939)(828)(709)(785)(282)(177)502

Interest expense——00(84)(143)(156)(121)(142)(253)

Interest & investment income——29331222596122111

Other income (expense), net1495454(27)(143)(342)(151)(200)(178)

Pre-tax income(410)(491)(761)(885)(856)(852)(1,127)(434)(377)323

Income tax expense00(1)(1)(3)(1)(4)(7)(99)(9)

Net income(410)(491)(761)(886)(858)(853)(1,131)(440)(278)314

EPS — basic———($8.11)($7.46)($7.20)($9.30)($3.52)($2.18)$2.39

EPS — diluted———($8.11)($7.46)($7.20)($9.30)($3.52)($2.18)$2.33

Shares outstanding — basic (M)———109115118122125128131

Shares outstanding — diluted (M)———109115118122125128135

Showing the latest 10 of 18 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.